CO44194
14 Sep 2023
CO44194
NCT05852691
A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Cancer Type | Breast |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | - |
Anticipated Start Date | 2023-07-18 |
Anticipated End Date | 2026-02-27 |
Hospital | Icon Cancer Centre - Tennyson and Windsor Garden |
---|---|
Clinical Trial Coordinator | Sue Yeend |
Sue.Yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Kerry Cheong |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs